Age verification

Age Verification Required

This website contains research peptides intended for laboratory use by qualified individuals aged 18 and over.

By continuing, you confirm that you are at least 18 years old and agree that all products are for research purposes only.

You must verify your age to access this site. This verification is stored for your current device.

CJC-1295 in Research: Mechanisms, Variants, and Protocols
← Back to Blog
Research7 min read

CJC-1295 in Research: Mechanisms, Variants, and Protocols

CJC-1295 is a growth hormone-releasing hormone analogue widely studied for its extended half-life and sustained GH stimulation. Learn what current research reveals.

Simplex Research Team·March 5, 2025

cjc-1295-research-guide.

Introduction

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It was engineered to extend plasma half-life by binding to serum albumin through a DAC (drug affinity complex) modification.

Mechanism of Action

CJC-1295 increases growth hormone release by:

  • Pituitary stimulationmimics endogenous GHRH signalling
  • Pulsatile GH releasepreserves natural secretory patterns
  • Albumin bindingDAC variant extends half-life to several days
  • IGF-1 elevationdownstream mediator of anabolic effects

With DAC vs Without DAC

FeatureCJC-1295 With DACCJC-1295 No DAC (Mod GRF 1-29)
Half-life~6–8 days~30 minutes
Dosing frequency1–2x per week1–3x per day
Albumin bindingYesNo
GH pulse qualitySustained elevationSharp, physiological pulses

Research Applications

Preclinical studies have investigated CJC-1295 for:

  1. **Body composition research** — lean mass and fat metabolism
  2. **Recovery models** — tissue repair and collagen synthesis
  3. **Aging research** — GH axis restoration in somatopause models
  4. **Sleep and cognition** — potential effects on REM sleep architecture

Research Considerations

The with-DAC variant produces a more sustained GH/IGF-1 elevation, which may be advantageous for some research models but can also increase water retention and insulin sensitivity considerations. Researchers should select the variant based on study design.

Conclusion

CJC-1295 remains a cornerstone GHRH analogue in peptide research. Its versatility across dosing schedules and variants makes it suitable for a wide range of preclinical investigations.

Cjc 1295 Research Summary

This article reviews the current research landscape around **cjc-1295**, highlighting key mechanisms, study findings, and practical considerations for laboratory use.

cjc-1295 Research Summary

This article reviews the current research landscape around **cjc-1295**, highlighting key mechanisms, study findings, and practical considerations for laboratory use.

Related Products

- Buy CJC-1295 (no DAC) 5MG

- Buy CJC-1295 w/ DAC 5MG

Related Research Reading

- Semaglutide in Research: Mechanisms and Studies

Explore Simplex Peptides

- Browse research peptides for sale

- Read more research articles

External Research Resources

- PubMed research on cjc 1295 mechanisms

- Peptide research literature on PubMed